Terms: = Kidney tumors AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1 AND Treatment
4 results:
1. Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study.
Nio Y; Ishida H; Matsumoto N; Kusumoto S; Kubota Y; Tsunoda T; Sasaki Y; Fujita KI
BMC Pulm Med; 2022 Nov; 22(1):454. PubMed ID: 36451169
[TBL] [Abstract] [Full Text] [Related]
2. Dimethoxycurcumin reduces proliferation and induces apoptosis in renal tumor cells more efficiently than demethoxycurcumin and curcumin.
Zanetti TA; Biazi BI; Coatti GC; Baranoski A; Marques LA; Corveloni AC; Mantovani MS
Chem Biol Interact; 2021 Apr; 338():109410. PubMed ID: 33582110
[TBL] [Abstract] [Full Text] [Related]
3. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Keisner SV; Shah SR
Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
[TBL] [Abstract] [Full Text] [Related]
4. Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin.
Hutson PR; Tutsch KD; Rago R; Arzoomanian R; Alberti D; Pomplun M; Church D; Marnocha R; Cheng AL; Kehrli N; Wilding G
Clin Cancer Res; 1998 Jun; 4(6):1429-36. PubMed ID: 9626459
[TBL] [Abstract] [Full Text] [Related]